Oncology disease screening and NLS technology with the Biophilia Tracker X3
Oncology disease screening and NLS technology with the Biophilia Tracker X3
Cancer screening. Screening is an organized measure designed to target disease exposure in people who do not themselves have clinical symptoms of the disease and who have no reason to seek medical care. Large-scale NLS research activities aimed at early diagnosis of oncological diseases have always had many proponents and opponents. This is due to the fact that tumor exposure in the preclinical stage does not always correspond to the term "early diagnosis". Currently, every tumor screening program has some clear basic requirements, including programs based on NLS technology and Biophilia Tracker X3; the disease must be sufficiently transmissible and of high social significance; Pre-exposure to disease is essential; there should be an opportunity to cure exposed disease with the help of existing technology; screening should reduce mortality in the population due to a specific disease; screening should be economically justified, That is, the cost of early diagnosis should be lower than the cost of treatment for patients, because patients have clinical symptoms to seek medical treatment.
Today, there is no doubt about the effectiveness of oncology screening. Over the past few years, major discussions on various aspects of these programs have spread, in particular:
Age limits, when it is appropriate to start and end screening procedures, depend on country characteristics;
Possibility of NLS for various localization assessment of cancer;
Current status of diagnostic techniques for primary and qualified oncological diseases.
There are other preclinical diagnostic procedures that are booming, such as early lung cancer exposure using dummy multivariate NLSoscopy, colorectal cancer-colonoscopy based dummy multivariate NLSoscopy combined with CT or MR. One of the most important outcomes is the early diagnosis of lung cancer case studies.
A modern fluoroscopic diagnostic procedure for investigating the possibility of bronchial cancer screening is based on the use of virtual helical NLS. The main advantage of this technique compared to rontgenography and fluorography is the fundamentally high resolution. The use of virtual NLS can effectively expose nidis of size 0,5-0,7 mm in lung tissue. In most major studies it has been shown that virtual NLS can reveal lung lesions in 10-12% of patients in a high-risk population, of which 0.5-1.5% are bronchial carcinomas. More than 80% of these tumors are undetected on rontgenography, which is limited to 3-5mm resolution. NLS can expose cancer in the first stage in 80-95% of patients.
The main limitations to widespread use of bronchial cancer screening are the high number of false-positive results and the lack of conclusive evidence of a reduction in mortality in the screening group compared with other groups or the entire population.